Online inquiry

IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10651MR)

This product GTTS-WQ10651MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10651MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15797MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ13181MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-04518600
GTTS-WQ7531MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ9869MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA K7153A
GTTS-WQ3332MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ6192MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CP-870893
GTTS-WQ7519MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ10690MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LymphoStat-B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW